World News and Views :: Top of the News
Lonza to Acquire Stake in German Biotech Firm
1:46 AM MDT | October 22, 2009 | Deepti Ramesh
Lonza says it has signed an investment agreement, including a right of first refusal for the commercial production of products, with innovative biotechnology company Cilian (Münster, Germany). Cilian uses the abilities of ciliates, eukaryotic single-cell micro-organisms, specifically the strain tetrahymena thermophila, for the production of therapeutic proteins and nutritional ingredients. Lonza owns a number of patents and patent applications in the field of tetrahymena thermophila and will transfer these patents and patent applications to Cilian. In...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee